信会师报字[2025]第ZI10405号 关于中广核核技术发展股份有限公司 2024 年度募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2025]第 ZI10405 号 ___ 报告编码:沪25MH 目录 第 1 -2 页 关于中广核核技术发展股份有限公司 2024 年度募集资金存放与使用情况 专项报告的鉴证报告 第 1 -9 页 中广核核技术发展股份有限公司 董事会关于募集资金 2024 年度存放与使用情 况的专项报告 立信会计师事务所(特殊普通合伙) EDO % BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LL 关于中广核核技术发展股份有限公司 2024年度募集资金存放与使用情况 专项报告的鉴证报告 中广核核技术发展股份有限公司全体股东: 我们接受委托,对后附的中广核核技术发展股份有限公司(以下 简称"中广核技"） 2024年度募集资金存放与使用情况专项报告(以 下简称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 中广核技董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号 -- 上市公司募集资金管理和 ...

中广核核技术发展股份有限公司 营业收入扣除情况鉴证报告 2024 年度 信会师报字[2025]第 ZI10406 号 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）" 进行 在对上述财务报表执行审计的基础上,我们接受委托,对后附的 中广核技2024年度营业收入扣除情况表（以下简称"营业收入扣除情 况表"）执行了合理保证的鉴证业务。 一、管理层的责任 中广核技管理层的责任是按照《深圳证券交易所股票上市规则》 和《深圳证券交易所上市公司自律监管指南第1号 -- 业务办理》的 相关规定编制营业收入扣除情况表,确保营业收入扣除情况表真实、 准确、完整,不存在虚假记载、误导性陈述或重大遗漏。 、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对营业收入扣除情况表 发表鉴证结论。 IBDO ≥ 立信会计师事务所(特殊普通合伙) BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTAN 关于中广核核技术发展股份有限公司2024年度 营业收入扣除情况表的鉴证报告 信会师报字[2025]第ZI10406号 中广核核技术发展股份有 ...

中广核核技术发展股份有限公司 内部控制审计报告 2024 年度 信会师报字[2025]第 ZI10403 号 您可使用手机"扫一扫" 此码用于证明该审计报告是否由具有执业许可的会计师事务 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）" 据告编 立信会计师事务所(特殊普通合伙) DO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS 内部控制审计报告 信会师报字[2025]第 ZI10403 号 中广核核技术发展股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关 要求,我们审计了中广核核技术发展股份有限公司(以下简称中广核技) 2024年12月31日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定,建立健全和有效实施内部控制,并评价其 有效性是中广核技董事会的责任。 . 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有 效性发表审计意见,并对注意到的非 ...

中广核核技术发展股份有限公司 关于收购项目利润承诺现金补偿履约情况的说明 ： 2024年度 信会师报字[2025]第 ZI10409 号 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查报 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查报 。 中广核技管理层的责任是按照中国证券监督管理委员会及深圳 证券交易所的信息披露相关规定及要求编制利润承诺现金补偿履约 情况说明,并保证其内容真实、准确、完整,以及不存在由于舞弊或 错误而导致的重大错报。我们的责任是在实施审核工作的基础上,对 利润承诺现金补偿履约情况说明发表审核意见。 我们按照《中国注册会计师其他鉴证业务准则第3101号-历史财 务信息审计或审阅以外的其他鉴证业务》的规定执行了审核工作,以 对利润承诺现金补偿履约情况说明是否不存在重大错报获取合理保 证。在执行审核工作的过程中,我们实施了询问、检查、重新计算等 我们认为必要的审核程序,选择的程序取决于我们的职业判断。我们 相信，我们的审核工作为发表审核意见提供了合理的基础。 我们认为,中 ...

公司各位独立董事严格遵守《公司法》《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》等法律 法规、中国证监会规定、证券交易所业务规则和《公司章程》《公司独立董事工 作制度》对独立董事的任职要求，对其自身独立性情况进行了严格、全面的自查。 根据公司独立董事黄晓延、康晓岳、王满签署的相关自查文件以及通过公开渠道 对其对外投资及任职情况的核查，上述人员未在本公司担任除独立董事及董事会 专门委员会委员以外的任何职务，未持有公司股份，上述人员及其直系亲属、主 要社会关系未在公司主要股东及其子企业担任任何职务，与公司及主要股东之间 不存在利害关系或其他可能妨碍其进行独立客观判断的关系，不存在影响独立性 的情况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监 管指引第1号——主板上市公司规范运作》中对独立董事独立性的相关要求。 中广核核技术发展股份有限公司 董事会 2025 年 4 月 25 日 中广核核技术发展股份有限公司 董事会关于独立董事独立性自查情况的专项意见 中广核核技术发展股份有限公司董事会对独立董事独立性情况进行评估并 出具专项意见如下: ...

中广核核技术发展股份有限公司 独立董事 2024 年度述职报告（康晓岳） 2024 年度，本人作为中广核核技术发展股份有限公司（以下简称"公司"）独立董事，严格 按照《公司法》《证券法》《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章和规范性文件以及《公司 章程》《独立董事工作制度》的有关规定，诚信、忠实、勤勉、专业地履行了独立董事职责，在 董事会日常工作及重要决策中尽职尽责，发挥了独立董事应有的作用，切实维护了股东尤其是中 小股东的合法权益。现将 2024 年度独立董事履职情况汇报如下： 一、独立董事的基本情况 （一）工作履历、专业背景及兼职情况 上市公司自律监管指引第 1 号——主板上市公司规范运作》中对独立董事独立性的相关要求。 二、独立董事年度履职概况 （一）出席董事会及股东会情况 | | | | | 参加董事会情况 | | | | 出席股东会情况 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 独立董事 姓名 | 应参加 董事会 | 现场出席 董事会 ...

中广核核技术发展股份有限公司 独立董事 2024 年度述职报告（黄晓延） 2024 年度，本人作为中广核核技术发展股份有限公司（以下简称"公司"）独立董事，严格 按照《公司法》《证券法》《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章和规范性文件以及《公司 章程》《独立董事工作制度》的有关规定，本着客观、公正、独立的原则和诚信、勤勉、尽责的 工作态度，积极出席公司股东会、董事会及专门委员会相关会议，认真审议董事会及专门委员会 各项议案，有效履行了独立董事职责，忠实行使了独立董事权利，充分发挥了独立董事应有的作 用，切实维护了股东尤其是中小股东的合法权益。现将 2024 年度独立董事履职情况汇报如下： 一、独立董事的基本情况 （一）工作履历、专业背景及兼职情况 本人黄晓延，1970 年生，2021 年 2 月 24 日经公司 2021 年第一次临时股东大会选举为公司 独立董事，同时担任公司薪酬委员会主任委员、战略委员会委员、提名委员会委员。医学物理师， 硕士研究生学历。本人在质子医疗领域具有丰富经验，曾任中山大学肿瘤防治中心新院区建 ...

中广核核技术发展股份有限公司 独立董事 2024 年度述职报告（孙光国） 本人未在公司担任除独立董事及董事会专门委员会委员以外的任何职务，未持有公司股份， 本人及本人直系亲属、主要社会关系也未在公司主要股东及其子企业担任任何职务，本人与公司 以及公司主要股东之间不存在利害关系或其他可能妨碍本人进行独立客观判断的关系，不存在 影响独立董事独立性的情况，符合《公司法》《上市公司独立董事管理办法》《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》中对独立董事独立性的相关要求。 二、独立董事年度履职概况 1 报告期内，公司共召开了 10 次董事会和 6 次股东会。本人通过现场或视频的方式亲自出席 了所有董事会和股东会，不存在缺席情况，本人不存在连续两次未亲自出席董事会会议的情形， 亦不存在任职期内连续十二个月未亲自出席董事会会议次数超过期间董事会会议总次数二分之 一的情形。 2024 年度，本人作为中广核核技术发展股份有限公司（以下简称"公司"）独立董事，严格 按照《公司法》《证券法》《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》等法律、 ...

Financial Performance - The company's operating revenue for 2024 was CNY 6,168,400,578, representing a decrease of 2.90% compared to CNY 6,352,518,940 in 2023[19]. - The net profit attributable to shareholders increased by 50.87% to CNY 198,751,228 in 2024, compared to CNY 199,594,590 in 2023[19]. - The company's net profit attributable to shareholders decreased to 512,783,647.00 CNY, a decline of 46.62% compared to the previous year[20]. - Operating cash flow increased to 456,344,040.00 CNY, representing a growth of 22.91% year-over-year[20]. - The gross margin for the irradiation processing services improved to 40%, up from 35% in the previous year, due to operational efficiencies[47]. - The company achieved a revenue of 6.168 billion RMB in 2024, with a net profit attributable to shareholders of -362 million RMB[72]. - The company reported a significant increase in revenue, reaching 1.2 billion yuan, representing a 15% year-over-year growth[44]. - The company reported a total revenue of 863.0 million, with a gross profit margin of 27.89%[126]. Business Strategy and Focus - The main business focus has shifted to electronic accelerator research and manufacturing, waste treatment, irradiation processing services, and new material development[17]. - The company is committed to enhancing its nuclear technology applications, particularly in medical health and new materials[17]. - The company is actively involved in various sectors, including material modification, disinfection, environmental governance, and medical technology, indicating a diversified business strategy[42]. - The company is focusing on the modification of materials, particularly in cable materials and heat-shrink materials, with strong demand from the semiconductor and electronic manufacturing sectors[34]. - The company is developing high-performance materials for various applications, including nuclear power and electronic devices, with several projects scheduled for completion in 2024[101]. - The company is focusing on the proton therapy system for cancer treatment, which has been included in the Ministry of Industry and Information Technology's "First Set Catalog (2024 Edition)"[71]. Research and Development - The company has established 14 R&D platforms and holds 270 authorized patents, with 121 R&D personnel, including 11 with postgraduate degrees[54]. - The company has invested 100 million yuan in R&D for new materials, focusing on biodegradable plastics and high-performance polymers[50]. - The company is focusing on the independent and innovative development of proton therapy equipment and key technologies for medical isotope production[64]. - The company filed 12 patents during the reporting period, including 4 inventions, and published 6 papers, contributing to its innovation capabilities[85]. - The company has completed the construction of a new production facility for automotive materials, with an investment of 524.4 million[124]. Market Expansion and Acquisitions - The company is expanding its market presence in Southeast Asia, targeting a 30% market share in the region by 2025[48]. - A strategic acquisition of a local competitor is anticipated to enhance the company's service capabilities and is expected to close by Q3 2024[49]. - The company is actively pursuing market expansion strategies, including potential mergers and acquisitions to enhance its competitive position[125]. - The company plans to expand its market presence through strategic acquisitions and partnerships in the upcoming fiscal year[122]. Operational Efficiency and Cost Management - The company reported a decrease in operational costs by 10% due to improved efficiency measures implemented in 2023[166]. - The company aims to reduce operational costs by 15% through efficiency improvements and technology upgrades[186]. - The company has achieved a production output of 6.299 million tons for polycarbonate materials, reflecting a growth of 5.17% year-over-year[125]. - The company reported a significant increase in production efficiency, with a 13.57% improvement in operational metrics compared to the previous year[125]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[4]. - The company has implemented a comprehensive risk management system and updated its compensation management policies[155]. - The company is addressing risks related to capital support for industrial development and optimizing its asset structure[143]. - The company has established a systematic development strategy for international markets, focusing on key regions such as Asia-Pacific, Europe, Africa, and the Americas[145]. Governance and Management - The company has a complete and independent business structure, not relying on any shareholders or related parties for operations[161]. - The company has established a remuneration and welfare management system that considers operational performance, individual job roles, and work assessments for determining compensation[192]. - The management team emphasized the importance of sustainability initiatives, with a commitment to invest 100 million RMB in green technologies[187]. - The company is focusing on enhancing corporate governance and oversight, as evidenced by the appointment of independent directors with significant industry experience[175][176]. Future Outlook - The company provided guidance for Q1 2024, expecting revenue to be between $1.6 billion and $1.8 billion, reflecting a growth rate of 15% to 20%[166]. - Future strategies include potential market expansion and the development of new technologies in the nuclear sector, aligning with industry trends towards sustainable energy solutions[170][172]. - The company plans to limit the growth of inventory balance to below the growth rate of sales in the new materials sector by 2025[149].

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,061,168,449.85, a decrease of 18.98% compared to ¥1,309,795,211.41 in the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥65,050,648.40, showing a slight improvement of 0.20% from a loss of ¥65,181,223.29 in the previous year[5]. - Net profit for the period was a loss of ¥65,822,026.06, compared to a loss of ¥62,597,662.69 in the previous period, indicating a worsening of approximately 4%[21]. - Total operating revenue decreased to ¥1,061,168,449.85 from ¥1,309,795,211.41, representing a decline of approximately 19% year-over-year[20]. - Total operating costs decreased to ¥1,144,000,244.83 from ¥1,397,561,395.19, a reduction of about 18% year-over-year[20]. Cash Flow - The net cash flow from operating activities improved by 15.92%, amounting to a loss of ¥31,986,734.41 compared to a loss of ¥38,042,141.21 in the same period last year[5]. - Cash flow from operating activities showed a net outflow of ¥31,986,734.41, an improvement from the previous outflow of ¥38,042,141.21[23]. - The cash inflow from operating activities totaled ¥1,286,802,573.45, down from ¥1,494,279,905.78, reflecting a decrease of approximately 14%[23]. - The company reported a 100% decrease in cash received from investment activities, totaling ¥0, as no financial products were invested during the period[11]. - Net cash flow from investing activities was -$80.43 million, compared to -$78.68 million in the previous period[24]. - Cash inflow from financing activities totaled $792.91 million, an increase from $769.28 million year-over-year[24]. - Cash outflow for financing activities was $720.36 million, up from $587.76 million in the prior period[24]. - Net cash flow from financing activities was $72.55 million, down from $181.52 million year-over-year[24]. - The net increase in cash and cash equivalents was -$40.49 million, compared to an increase of $56.62 million in the previous period[24]. - The ending balance of cash and cash equivalents was $1.41 billion, down from $1.08 billion year-over-year[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥10,531,535,935.17, down 1.60% from ¥10,702,263,483.90 at the end of the previous year[5]. - The total liabilities of the company were CNY 5,047,592,003.11, down from CNY 5,153,939,405.01, representing a decrease of about 2.06%[18]. - Current assets decreased from CNY 6,288,748,438.55 to CNY 6,123,112,485.46, reflecting a decline of approximately 2.63%[17]. - The company's cash and cash equivalents stood at CNY 1,444,595,152.03, down from CNY 1,490,786,138.55, indicating a decrease of about 3.09%[17]. - Accounts receivable decreased from CNY 2,185,366,416.81 to CNY 1,998,990,892.90, a reduction of approximately 8.52%[17]. - Short-term borrowings increased from CNY 1,421,274,006.42 to CNY 1,523,354,808.80, an increase of approximately 7.16%[18]. - The company's equity attributable to shareholders decreased by 1.22%, totaling ¥5,166,300,823.27 compared to ¥5,230,122,212.51 at the end of the previous year[5]. - The company reported a total of 6,123,112,485.46 in current assets, which includes inventory valued at CNY 1,157,707,047.69, an increase from CNY 1,077,521,780.98[17]. - The company has a total of 12,083,642.39 in long-term equity investments, slightly down from 12,271,027.06[17]. Shareholder Information - The company has a significant shareholder, China General Nuclear Power Corporation, holding 28.67% of the shares[15]. Other Financial Metrics - Financial expenses decreased by 51.55% to ¥11,285,475.09, mainly due to increased interest income and exchange gains[10]. - The cash received from tax refunds increased by 80.27% to ¥37,710,701.54, primarily due to an increase in VAT refunds related to medical business[11]. - Research and development expenses decreased to ¥34,383,142.51 from ¥42,425,323.66, a reduction of about 19% year-over-year[20]. - Other comprehensive income after tax increased to ¥1,063,100.31 from ¥158,922.00, showing significant improvement[21]. - The company reported a basic and diluted earnings per share of -0.0688, consistent with the previous period's -0.0689[22]. - The company recorded an investment loss of ¥1,088,206.47, contrasting with a gain of ¥1,879,918.37 in the previous period[20]. Accounting and Reporting - The company has not audited its first-quarter report[25]. - The new accounting standards will be implemented starting in 2025[26].